Navigation Links
UNC, Yale partner to study effects of cocaine use on mother-infant relationships

CHAPEL HILL Researchers from the University of North Carolina at Chapel Hill and Yale University have been awarded almost $10 million to study the many ways cocaine use during pregnancy can negatively affect interactions between mothers and their infants.

The project's researchers hope their findings will aid the development of new intervention strategies for helping both mothers and children, and prove valuable to others working in fields such as drug abuse and developmental disorders.

Josephine Johns, Ph.D., associate professor of psychiatry and psychology at UNC, is the principal investigator and project director of the study. Linda Mayes, M.D., professor of child psychiatry, pediatrics and psychology at Yale, is principal investigator for the portion of the study conducted there.

"The scientific tools and methods developed and used for the project, as well as the new information it will provide about the basis of maternal-infant interactions, should prove beneficial for behavioral or biological intervention strategies," Johns said.

"For example, if specific types of cries are found to elicit negative feelings or responses from mothers, on a very basic level we can work with mothers to make them aware of why these cries might be uncomfortable and develop methods for coping and responding to their babies in a more positive fashion," she said.

The study will consist of three separate projects, supported by shared neuroimaging and data analysis teams. Project 1, based at UNC, will examine the effects of cocaine on mother-infant interactions in rodents. Researchers will examine the brain development of infants exposed to cocaine and how that exposure affects their ability to regulate body temperature, hormones and other bodily processes. The project will also determine how cocaine use during pregnancy affects mothers' brain structures and hormonal systems, alters their genetic responses and affects how mothers respond to specific kinds of cues from their babies, such as cries.

Projects 2 and 3 will study similar measures to Project 1, but will focus on human pairs of mothers and infants, including mothers who used cocaine during pregnancy and those who did not. Project 2, also based at UNC, will examine mothers' emotional and hormonal responses when feeding and cuddling their infants, and to baby-related cues such as cries and pictures of babies. Researchers will also study how cocaine exposure during pregnancy affects babies' early brain development, whether their cries have different sound characteristics, and behavioral factors that may affect mother-infant interaction.

Project 3, which is based at Yale, will focus on using functional brain imaging scans, or fMRI technology, to study how mothers' brains react to many of the same stimulus cues used in Project 2, as well as how particular genes may modify key aspects of early maternal sensitivity to infants' cues.

"Understanding, for example, how genes and experiences such as substance use come together to influence how a mother responds to her baby's cry or other expressions of distress sets the stage for working towards finding innovative interventions for adults who are struggling to care for their children under the burden of their own substance use," Mayes said.

All studies will also focus on the role of the hormone oxytocin, which has been identified as playing an important role in human child birth, production of breast milk and response to stress, and has also been directly associated with early maternal care and social behavior in laboratory rodents. Previous studies in Johns' lab found that rodent mothers exposed to cocaine during and just after pregnancy provided poorer care to their pups, which correlated with disruptions of the oxytocin system.


Contact: Tom Hughes
University of North Carolina School of Medicine

Related biology news :

1. Elsevier partners with the Royal Netherlands Society for Agricultural Sciences
2. NIH funds 16 Science Education Partnership Awards
3. GUMC and Oak Ridge National Labs announce unique research partnership
4. Alzheimers disease research attracts first partner
5. Annual meeting of Big Sky Carbon Sequestration Partnership to be held Oct. 28, 29
6. UCLA, partners establish new center on environmental effects of nanotechnology
7. Syracuse University partners with Serum Institute of India to develop vaccines for children
8. Carbon Disclosure Project, ICLEI partner to help US cities report local climate actions, emissions
9. ASM and FIND to partner on strengthening infectious disease diagnosis in developing nations
10. IBM and ETH Zurich form strategic partnership in nanoscience
11. Gladstone and Izumi Bio in partnership in regenerative medicine and cardiovascular disease
Post Your Comments:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology: